|Application ||WB, IHC-P, IF, FC, E|
|Other Accession||P70428, O77783|
|Calculated MW||82255 Da|
|Antigen Region||182-209 aa|
|Other Names||Exostosin-2, Glucuronosyl-N-acetylglucosaminyl-proteoglycan/N-acetylglucosaminyl-proteoglycan 4-alpha-N-acetylglucosaminyltransferase, Multiple exostoses protein 2, Putative tumor suppressor protein EXT2, EXT2|
|Target/Specificity||This EXT2 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 182-209 amino acids from the Central region of human EXT2.|
|Format||Purified polyclonal antibody supplied in PBS with 0.09% (W/V) sodium azide. This antibody is purified through a protein A column, followed by peptide affinity purification.|
|Storage||Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.|
|Precautions||EXT2 Antibody (Center) is for research use only and not for use in diagnostic or therapeutic procedures.|
|Function||Glycosyltransferase required for the biosynthesis of heparan-sulfate. The EXT1/EXT2 complex possesses substantially higher glycosyltransferase activity than EXT1 or EXT2 alone. Appears to be a tumor suppressor. Required for the exosomal release of SDCBP, CD63 and syndecan (PubMed:22660413).|
|Cellular Location||Endoplasmic reticulum membrane; Single-pass type II membrane protein. Golgi apparatus membrane; Single-pass type II membrane protein. Note=The EXT1/EXT2 complex is localized in the Golgi apparatus|
firstname.lastname@example.org, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
EXT2 encodes one of two glycosyltransferases involved in the chain elongation step of heparan sulfate biosynthesis.
Zhao, J., et al. Diabetes 59(3):751-755(2010)
Li, Y., et al. Genet Test Mol Biomarkers 13(6):825-830(2009)
Yerges, L.M., et al. J. Bone Miner. Res. 24(12):2039-2049(2009)
Heinritz, W., et al. Ann. Hum. Genet. 73 (PT 3), 283-291 (2009)
Cornelis, M.C., et al. Ann. Intern. Med. 150(8):541-550(2009)
If you have any additional inquiries please email technical services at email@example.com.